Interest in using psychedelics for mental health treatments has taken off in recent years — but the field was just dealt a major blow on August 9, when the Food and Drug Administration rejected a bid by Lykos Therapeutics to approve the first-ever MDMA treatment for PTSD. The agency said it needed more research to show that the drug was safe and effective. The decision means that an active research community that has formed over the last few decades will likely continue as it started — more underground than above ground.
On this episode of The Pulse, we look at the latest on psychedelics and mental health, along with the challenges to moving the research forward. We hear stories about the battle over MDMA, new questions about whether ketamine can actually help treat depression, and a group that says it’s found the solution to cluster headaches in psilocybin.
Transcript and audio here
The promise and future of psychedelics research
